Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Tasquinimod clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Prostate Cancer & Advanced or Metastatic Hepatocellular Cancer) and 2,052 total planned enrollment. 2 Phase 3 Tasquinimod trials and 4 Phase 2 are listed. 2 Tasquinimod clinical trials are actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT06327100 (May 2031).
Where to Participate: All Tasquinimod Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting Tasquinimodtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
PMFOpen Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT04405167terminatedTasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT02396368withdrawnA Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
NCT02057666terminatedStudy Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT01732549terminatedA Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
All Tasquinimod trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
11 Tasquinimod clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 5 are marked completed.
Are Tasquinimod clinical trials recruiting in 2026?
Yes — 2 Tasquinimod trials are actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
What conditions is Tasquinimod being studied for?
Tasquinimod is being studied for Prostate Cancer, Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC), Hormone-Resistant Prostate Cancer and 12 more. The trials are grouped by indication on this page.
What phase is Tasquinimod in?
Tasquinimod clinical trials span 2 Phase 3, 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tasquinimod clinical trials?
The lead sponsor across the most Tasquinimod trials is Ipsen, with 7 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tasquinimodas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.